Am J Psychiatry 1979; 136:187-190
Copyright © 1979 by American Psychiatric Association
Lorazepam, a new benzodiazepine derivative, in the treatment of anxiety: a double-blind clinical evaluation
L McCurdy
Ninety-five adult outpatients suffering from moderate to severe anxiety
were randomly assigned to treatment with lorazepam or placebo in a
double-blind four-week study. Patients were evaluated at pretreatment and
after two and four weeks of treatment using three rating scales. Lorazepam,
at an average daily dose of 3.2 mg twice daily, was highly effective in
relieving anxiety as documented by clinically and statistically significant
differences over placebo in most of the items on all rating scales at all
rating periods. No serious adverse effects were reported, and there were no
adverse interactions with other medications, including digitalis and
aspirin.
